Lin BioScience, Inc.
6696
Ранг среди акций
#3911
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Цена акции
$5.03
Рыночная капитализация
$4.17B
Изменение (1 день)
-5.81%
Изменение (1 год)
-44.72%
Страна
TW
Торговля Lin BioScience, Inc. (6696)
Категория
Healthcare
История цены акций Lin BioScience, Inc. (6696)
Наивысшая цена закрытия: $5.40 2026-10-01
Наименьшая цена закрытия: $1.30 2018-10-01
Наименьшая цена закрытия: $1.30 2018-10-01
История цены акций Lin BioScience, Inc. с 2018 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $756.75 | 7.56% |
CH
|
